The BabyMERIT trial will evaluate trametinib in infants with Noonan syndrome and related conditions who develop severe hypertrophic cardiomyopathy, a potentially life-threatening condition. The study aims to improve outcomes for these young patients by targeting a molecular pathway known to drive these disorders.
Researchers at Mount Sinai will test a community-based primary care model to address high blood pressure in rural Ghana. The approach aims to provide care through community health workers and nurses, with a 90% success rate in a pilot study.
A study found that stimulation of specific brain connections, including the cingulum bundle, forceps minor, and medial uncinate fasciculus, is associated with sustained clinical improvement in patients with treatment-resistant depression. The findings support connectome-based targeting for deep brain stimulation and may help researcher...
Researchers will study brain activity, cardiovascular function, and accelerated aging in orbit using bioengineered human brain and cardiovascular tissue models. The findings could help identify new ways to protect astronauts' heart health and inform new therapies for cardiovascular disease.
Researchers at Mount Sinai develop Vaccine Immunoengineering for Targeted Antigen Presentation and Layered Control (VITAL) to create improved vaccines against respiratory pathogens. The program aims to explore new strategies for generating long-lasting immune protection against a range of virus variants.
A new study found that adding safety prompts to AI models can reduce potentially harmful clinical choices by 10.1%, emphasizing the importance of evaluating not only accuracy but also safety in AI decision-making. The researchers propose building automated safety testing into AI system development and evaluation to strengthen safeguards.
Dr. Veress leads research strategy and infrastructure in the Department of Pediatrics, aiming to bring innovative ideas from lab and clinical settings to treatments. She will also oversee pediatric pulmonology across the Mount Sinai Health System, expanding care for children with complex respiratory conditions.
The Mount Sinai Tisch Cancer Center has implemented a real-time EHR-to-EDC technology platform, reducing clinical trial data-entry time by over half and improving data accuracy. The platform automatically transfers 70% of data with 100% accuracy, freeing up research teams to focus on patient care and advancing research.
A new five-year study, supported by a $3.3 million NIH grant, will investigate the link between PFAS exposure and IBD, with researchers exploring biological changes that occur years before diagnosis. The study aims to uncover mechanisms that could help identify individuals at risk and inform prevention strategies.
Napoleone Ferrara, MD, has been awarded the 2026 Yergin Family International Prize for Biomedical Research for his discovery of vascular endothelial growth factor (VEGF), a molecule that plays a key role in abnormal blood vessel growth in cancer and blinding eye diseases. His research led to the development of treatments that have bene...
Mount Sinai has launched an international clinical trial to determine the optimal treatment for spontaneous coronary artery dissection (SCAD), a sudden tear in the wall of a heart artery that can reduce blood flow and cause an uncommon type of heart attack. The trial, known as SCAD-ALIGN, will compare a moderate antiplatelet strategy o...
A Mount Sinai study reveals that loss of p53 can reorganize Wnt signaling into a radial gradient, allowing mutant cells to expand through normal tissue. The researchers found that the spatial organization of Wnt signaling, rather than its overall activity, plays a critical role in this process.
Mount Sinai researchers have identified a brain circuit, the anterior hypothalamic nucleus (AHN), that helps explain how prior adversity makes the brain more reactive to future stress. The study found that dialing AHN activity up or down directly altered how strongly mice responded to stress.
A new study found that a noninvasive magnetic therapy headset improved cognitive function and mood in people with long COVID, with effects persisting after treatment ended. The therapy, called Microtesla Magnetic Therapy, showed anti-inflammatory and neuroprotective effects in preclinical models.
Researchers developed an AI approach using wearable data to forecast prolonged sitting in women with chronic pelvic pain. The study analyzed data from 134 women with chronic pelvic pain disorders and found that relatively simple, interpretable models accurately forecasted prolonged sitting.
Mount Sinai researchers collaborate with Johnson & Johnson to evaluate a liquid radioembolic agent for treating brain tumors. The agent combines radiation delivery and embolization to target tumors, offering a new approach for managing difficult-to-remove tumors.
Researchers found persistent CAR-T cells and widespread immune disruption in patients who develop severe intestinal inflammation after CAR-T therapy. JAK inhibitors showed promise in treating the condition, with some patients experiencing significant symptom improvements.
Mount Sinai researchers identified how APOE4 damages brain blood vessels, promoting abnormal protein buildup and neurodegeneration. They found that blocking TGF-β signaling restored pericyte coverage, reducing fibrosis and vascular amyloid accumulation.
Researchers identified shared and disease-specific molecular changes in human brain tissue, contributing to neurodegeneration, psychiatric illness, and cognitive decline. The collection establishes a foundational resource for understanding brain disorders, accelerating discovery and therapy development.
Researchers have identified candidate treatment targets for high-grade glioma in children, adolescents, and young adults, with distinct tumor biology and outcomes across patient groups. The study found that kinases, including CDK8, ATM, and ATR, may suppress oxidative phosphorylation and are potential targets for therapy.
A large neuroimaging study found structural brain differences in individuals with bulimia nervosa, particularly in regions involved in reward and motivation, social and sensory processing. More frequent binge eating was associated with more widespread differences in brain structure.
Researchers have discovered a rare population of neurons in the cortex that can synchronize activity across large areas of the brain and promote sleep. These Sst-Chodl neurons were found to be active during the transition to sleep and could even help drive the process, suggesting that the cortex is not simply passive during sleep.
A study published in Nature Communications found that living in hotter, more polluted neighborhoods with limited green space increases the risk of frailty, PTSD, and depression among World Trade Center responders. In contrast, greener environments were associated with lower risks of these conditions.
Researchers found that pancreatic cancer cells create localized immune-protective niches that shield tumors from immune attack. Disrupting these protective mechanisms slowed tumor growth and improved responses to immunotherapy in preclinical models.
A new study suggests that carefully selected patients with recurrent DIPG may experience longer survival and improved quality of life after receiving a third course of radiation therapy. The study analyzed 12 patients and found that median survival was 27 months, substantially longer than typically reported for DIPG.
The new center aims to better understand diseases and treatment response by combining human genetics and microbiome research with AI. Researchers will investigate how genetic variation and the gut microbiome jointly shape disease progression and treatment response.
The study aims to improve health and quality of life for people with sickle cell disease by understanding the impact of daily life on the disease. Researchers will measure everyday exposures, including air quality, temperature, food, and stress, to develop tools for clinicians to counsel patients.
A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.
A chemotherapy-free combination of targeted therapies showed encouraging results in patients with HR-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option. The regimen produced durable responses while maintaining a manageable safety profile for many patients.
Mount Sinai will deliver healthcare services to elite tennis players, focusing on promoting health and wellness, preventing injuries, and meeting community needs. The partnership highlights the importance of access to specialized medical services for athletes competing at the highest level.
Mount Sinai scientists reveal how the brain represents leader and follower roles through prefrontal cortex activity, and create an AI that decodes hidden goals behind teamwork. The study shows that leadership is an asymmetric yet bidirectional partnership, and that followers play a crucial role in maintaining cooperation.
A systematic review of 35 studies involving 2,108 patients found that patients who underwent posterior spinal fusion with posterior column osteotomies had similar overall correction compared to those who underwent PSF without PCOs. PCOs may be useful in select patients with larger or stiffer curves.
Researchers identified TIMP2 as a key factor supporting healthy microglial function in the aging brain. Restoring TIMP2 in aged mice improved microglia's ability to clear debris and reduced inflammation, suggesting potential therapeutic strategies for neurodegenerative disorders.
A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
Researchers at Mount Sinai have been selected as Milestone 2 Awardee teams in XPRIZE Healthspan, a global competition that aims to develop new approaches for healthy aging. The NYC-Vita clinical trial will evaluate lifestyle and pharmaceutical interventions designed to improve immune system function and support healthier aging.
Researchers identified a protective subtype of microglia that expands as Alzheimer's disease progresses, playing a key role in clearing harmful material from the brain. The study provides insights into how the brain's immune cells change across the lifespan and throughout Alzheimer's disease, paving the way for therapies that strengthe...
Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk of recurrence after surgery. Nearly 80% of patients who received this treatment remained free of disease progression, recurrence, or death two years after treatment began.
Researchers utilized a large healthcare system biobank to identify individuals carrying rare copy number variants linked to neurodevelopmental disorders. The study found significant value in direct phenotyping, providing practical benchmarks for implementing recall-by-genotype studies in diverse healthcare systems.
Researchers have uncovered the first high-resolution structure of NBCn2, a brain protein linked to epilepsy, autism spectrum disorder, and other neurological conditions. The team developed compounds capable of inhibiting its activity, which may help advance therapeutic research for these disorders.
Researchers identified unique antibody signatures against viruses and bacteria in nearly 2,000 blood samples collected over a decade, showing immune system changes years before diagnosis. The study supports the theory of molecular mimicry and provides an important framework for understanding IBD's earliest stages.
The new center at Mount Sinai will join the Colton Consortium for Autoimmunity, expanding research on earlier detection, precision treatment, and disease prevention for people with autoimmune diseases. The Center aims to develop more precise, effective treatments across multiple diseases by understanding shared immune pathways.
A new review proposes a roadmap for developing cognitive brain-computer interfaces to treat cognitive disorders, integrating BCI research and clinical neuromodulation. The emerging field aims to detect dysfunctional brain states and respond with adaptive neurostimulation.
A Mount Sinai study found that single-cell atlases, used for mapping the human body and training AI models, may not accurately represent global populations. The analysis of over 13,500 samples revealed an overrepresentation of European ancestry and underrepresentation of Asian and Latino individuals, highlighting the need for diverse a...
A study published in Science reveals that dendritic cells build and maintain structures called tertiary lymphoid structures (TLSs) within tumors, which serve as local command centers for the immune system. These hubs play a key role in antitumor immunity and may be a target for future therapies.
Researchers found that prenatal and early-life exposure to PFAS is associated with increased intestinal inflammation in childhood, as measured by elevated fecal calprotectin levels. This study suggests that environmental exposures during critical stages of development may influence long-term intestinal health and future inflammatory bo...
A nationwide analysis found that many radiation oncology clinics have closed, particularly in rural communities, reducing access to lifesaving cancer treatment. The study suggests that understanding which communities are most vulnerable can help policymakers develop strategies to preserve access.
Researchers at Mount Sinai will investigate biological mechanisms driving peanut allergy desensitization, identifying biomarkers for patient prediction and advancing personalized treatment strategies. The INROADS center aims to improve treatment outcomes and accessibility for patients with peanut allergy.
Researchers found that patients with Parkinson's disease showing little to no Lewy bodies despite long-standing, clinically advanced disease. The study provides new insight into the relationship between clinical symptoms and neuropathological progression.
Researchers have developed a dual-targeting strategy to combat emerging infectious diseases. A fully human monoclonal antibody cocktail provides complete protection against lethal Nipah virus infection, even when treatment is given after infection has begun.
The Mount Sinai Adolescent Health Center has received the 2026 Community Health Improvement Award from HANYS, recognizing its decades-long leadership in comprehensive, confidential, equitable care for adolescents and young adults. The award honors the Center's commitment to improving public health and advancing health equity.